Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients
IntroductionBooster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact of homologous and heterologous booster doses in neutralizing antibody (NAb) titers and their ability to interfere with the variant of concern Omicron are not well...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1135478/full |
| _version_ | 1827990569029206016 |
|---|---|
| author | Aracelly Gaete-Argel Aracelly Gaete-Argel Vicente Saavedra-Alarcón Denis Sauré Luis Alonso-Palomares Mónica L. Acevedo Mónica L. Acevedo Marion Alarcón Susan M. Bueno Susan M. Bueno Alexis M. Kalergis Alexis M. Kalergis Alexis M. Kalergis Ricardo Soto-Rifo Ricardo Soto-Rifo Fernando Valiente-Echeverría Fernando Valiente-Echeverría Claudia P. Cortes Claudia P. Cortes Claudia P. Cortes |
| author_facet | Aracelly Gaete-Argel Aracelly Gaete-Argel Vicente Saavedra-Alarcón Denis Sauré Luis Alonso-Palomares Mónica L. Acevedo Mónica L. Acevedo Marion Alarcón Susan M. Bueno Susan M. Bueno Alexis M. Kalergis Alexis M. Kalergis Alexis M. Kalergis Ricardo Soto-Rifo Ricardo Soto-Rifo Fernando Valiente-Echeverría Fernando Valiente-Echeverría Claudia P. Cortes Claudia P. Cortes Claudia P. Cortes |
| author_sort | Aracelly Gaete-Argel |
| collection | DOAJ |
| description | IntroductionBooster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact of homologous and heterologous booster doses in neutralizing antibody (NAb) titers and their ability to interfere with the variant of concern Omicron are not well studied.MethodsWe designed a prospective, open-label, observational clinical cohort study. 45 participants received two doses of BNT162b2 or CoronaVac (21-day or 28-day intervals, respectively) followed by a first and second booster with BNT162b2 (5-month apart each) and we analyzed the neutralizing antibody titers against SARSCoV-2 D614G (B.1 lineage) and Omicron (BA.1 lineage).ResultsOur results show that SOTRs receiving an initial two-dose scheme of CoronaVac or BNT162b2 generate lower NAbs titers against the ancestral variant of SARS-CoV-2 when compared with healthy controls. Although these NAb titers were further decreased against the SARS-CoV-2 Omicron, a single BNT162b2 booster in both groups was sufficient to increase NAb titers against the variant of concern. More importantly, this effect was only observed in those participants responding to the first two shots but not in those not responding to the initial vaccination scheme.DiscussionThe data provided here demonstrate the importance of monitoring antibody responses in immunocompromised subjects when planning booster vaccination programs in this risk group. |
| first_indexed | 2024-04-10T00:37:26Z |
| format | Article |
| id | doaj.art-72f56cbebb094dc19df8a6b1e11c4057 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T00:37:26Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-72f56cbebb094dc19df8a6b1e11c40572023-03-14T13:22:01ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-03-011410.3389/fimmu.2023.11354781135478Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipientsAracelly Gaete-Argel0Aracelly Gaete-Argel1Vicente Saavedra-Alarcón2Denis Sauré3Luis Alonso-Palomares4Mónica L. Acevedo5Mónica L. Acevedo6Marion Alarcón7Susan M. Bueno8Susan M. Bueno9Alexis M. Kalergis10Alexis M. Kalergis11Alexis M. Kalergis12Ricardo Soto-Rifo13Ricardo Soto-Rifo14Fernando Valiente-Echeverría15Fernando Valiente-Echeverría16Claudia P. Cortes17Claudia P. Cortes18Claudia P. Cortes19Laboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Santiago, ChileLaboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, ChileDepartamento de Ingenieria Industrial, Facultad de Ciencias Físicas y Matemáticas, University of Chile and Institutos Sistemas Complejos de Ingenieria, Santiago, ChileLaboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, ChileLaboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Santiago, ChileClínica Santa María, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, ChileDepartamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, ChileLaboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Santiago, ChileLaboratorio de Virología Molecular y Celular, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Santiago, ChileMillennium Institute on Immunology and Immunotherapy, Santiago, ChileClínica Santa María, Santiago, ChileDepartamento de Medicina Interna Centro, Facultad de Medicina, Universidad de Chile, Santiago, ChileIntroductionBooster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact of homologous and heterologous booster doses in neutralizing antibody (NAb) titers and their ability to interfere with the variant of concern Omicron are not well studied.MethodsWe designed a prospective, open-label, observational clinical cohort study. 45 participants received two doses of BNT162b2 or CoronaVac (21-day or 28-day intervals, respectively) followed by a first and second booster with BNT162b2 (5-month apart each) and we analyzed the neutralizing antibody titers against SARSCoV-2 D614G (B.1 lineage) and Omicron (BA.1 lineage).ResultsOur results show that SOTRs receiving an initial two-dose scheme of CoronaVac or BNT162b2 generate lower NAbs titers against the ancestral variant of SARS-CoV-2 when compared with healthy controls. Although these NAb titers were further decreased against the SARS-CoV-2 Omicron, a single BNT162b2 booster in both groups was sufficient to increase NAb titers against the variant of concern. More importantly, this effect was only observed in those participants responding to the first two shots but not in those not responding to the initial vaccination scheme.DiscussionThe data provided here demonstrate the importance of monitoring antibody responses in immunocompromised subjects when planning booster vaccination programs in this risk group.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1135478/fullCOVID-19humoral responseneutralizationorgan transplantationvaccine |
| spellingShingle | Aracelly Gaete-Argel Aracelly Gaete-Argel Vicente Saavedra-Alarcón Denis Sauré Luis Alonso-Palomares Mónica L. Acevedo Mónica L. Acevedo Marion Alarcón Susan M. Bueno Susan M. Bueno Alexis M. Kalergis Alexis M. Kalergis Alexis M. Kalergis Ricardo Soto-Rifo Ricardo Soto-Rifo Fernando Valiente-Echeverría Fernando Valiente-Echeverría Claudia P. Cortes Claudia P. Cortes Claudia P. Cortes Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients Frontiers in Immunology COVID-19 humoral response neutralization organ transplantation vaccine |
| title | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
| title_full | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
| title_fullStr | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
| title_full_unstemmed | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
| title_short | Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients |
| title_sort | impact of homologous and heterologous boosters in neutralizing antibodies titers against sars cov 2 omicron in solid organ transplant recipients |
| topic | COVID-19 humoral response neutralization organ transplantation vaccine |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1135478/full |
| work_keys_str_mv | AT aracellygaeteargel impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT aracellygaeteargel impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT vicentesaavedraalarcon impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT denissaure impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT luisalonsopalomares impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT monicalacevedo impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT monicalacevedo impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT marionalarcon impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT susanmbueno impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT susanmbueno impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT alexismkalergis impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT alexismkalergis impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT alexismkalergis impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT ricardosotorifo impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT ricardosotorifo impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT fernandovalienteecheverria impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT fernandovalienteecheverria impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT claudiapcortes impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT claudiapcortes impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients AT claudiapcortes impactofhomologousandheterologousboostersinneutralizingantibodiestitersagainstsarscov2omicroninsolidorgantransplantrecipients |